Three-way play on cosmeceuticals

Spurred on by the success of Rogaine and other prescription drugs that are marketed as treatments for cosmetic conditions, Oncogene Science Inc. and Pfizer Inc. have brought in researchers from New York University and extended their partnership to include development of "cosmeceuticals."

The collaborators announced their intention to form a new company, Anaderm Research Corp., to develop products for skin conditions such as wrinkles and pigmentation abnormalities as well as baldness. Anaderm will be 82 percent owned by Pfizer, ONCS will have a 14 percent stake and NYU will have the option to acquire 4 percent of the company. ...